Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia
RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
- RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
- In this successful Phase 1b trial, RJx-01 met all primary and secondary endpoints.
- Rejuvenate Biomed is gearing up to initiate a Phase 2 program focused on RJx-01 in the treatment of sarcopenia in 2024.
- Subsequently, they were closely monitored during the immobilization phase and for an additional four weeks post-cast removal in the recovery phase.